MaxCyte unveils ExPERT DTx™, a 96-well electroporation platform to accelerate discoveryGlobeNewsWire • 02/24/26
MaxCyte to Report Fourth Quarter and Full Year 2025 Financial Results on March 24, 2026GlobeNewsWire • 02/23/26
MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 01/12/26
Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPOBusiness Wire • 12/01/25
MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue GuidanceGlobeNewsWire • 11/12/25
MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue GuidanceGlobeNewsWire • 11/05/25
MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid TumorsGlobeNewsWire • 10/06/25
MaxCyte Announces Operational Restructuring to Reduce Costs and Accelerate Path to ProfitabilityGlobeNewsWire • 09/22/25
MaxCyte Announces Strategic Platform Licensing Agreement with Anocca AB to Advance TCR-T Cell Therapy PipelineGlobeNewsWire • 07/31/25
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular TherapiesGlobeNewsWire • 06/11/25
MaxCyte Reports First Quarter 2025 Financial Results and Reiterates Full Year 2025 GuidanceGlobeNewsWire • 05/07/25
Down -27.78% in 4 Weeks, Here's Why You Should You Buy the Dip in MaxCyte (MXCT)Zacks Investment Research • 04/08/25
Down -30.2% in 4 Weeks, Here's Why MaxCyte (MXCT) Looks Ripe for a TurnaroundZacks Investment Research • 04/07/25